Prevnar13

BIOLOGICAL10 trials

Conditions

Acellular PertussisChronic Lymphocytic LeukemiaCoronavirus InfectionDiphtheriaDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b VaccinesHaemophilus Influenzae Type bHepatitis BInfections, Meningococcal

Phase 1

A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults

NCT03549208

LG ChemPneumococcal Infection

Start: 2018-07-01End: 2019-07-25Target: 60Updated: 2018-06-13

Phase 2

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

TerminatedNCT03376477

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMultiple Myeloma

Start: 2019-09-23End: 2025-05-30Updated: 2025-08-27

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

CompletedNCT03467984

LG ChemPneumococcal Infection

Start: 2018-05-25End: 2019-03-27Updated: 2019-08-22

Phase 3

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

CompletedNCT02096263

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +3

Start: 2014-04-16End: 2015-11-13Updated: 2019-11-27

Immunogenicity and Safety Study of NBP606 in Healthy Infants

CompletedNCT02201030

SK Chemicals Co., Ltd.Pneumococcal Infections

Start: 2014-09-06End: 2016-10-21Updated: 2020-04-20

Immunogenicity and Safety Study of NBP606 in Healthy Toddlers

CompletedNCT02927444

SK Chemicals Co., Ltd.Pneumococcal Infections

Start: 2015-11-04End: 2017-10-26Updated: 2020-04-20

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

CompletedNCT03621670

GlaxoSmithKlineInfections, Meningococcal

Start: 2018-07-27End: 2024-12-27Updated: 2026-02-10

Phase 4

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

CompletedNCT02422264

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines +2

Start: 2016-01-22End: 2018-03-07Updated: 2019-07-09

Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs

NCT04978038

Mark LoebCoronavirus Infection, SARS-CoV2 Infection

Start: 2022-08-01End: 2022-12-31Target: 414Updated: 2022-06-30

Unknown Phase

Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia

NCT05145101

Hannah Garcia GarridoChronic Lymphocytic Leukemia, Invasive Pneumococcal Disease, Recurrent Isolated, Pneumococcal Infections +1

Start: 2020-05-07End: 2022-03-31Target: 150Updated: 2021-12-20

Open Forum Infectious Diseases2026-01-01

Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial

Vaccine2021-02-2112 citations

Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.

2019-11-2420 citations

Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and <i>Haemophilus influenzae</i> type b vaccine: a randomized trial in the United States

Human Vaccines & Immunotherapeutics2018-11-2016 citations